Key events, in time order
PT raised from $641, but rating unchanged, reflecting cautious optimism
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
13F filing shows 9.11M shares acquired, signaling institutional inflow
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
None yet
None yet
Regeneron's advertising for Dupixent and Eylea HD is increasing, suggesting a potential upcoming catalyst or growth phase for the company.
Main discussion
$REGN ads for Dupixent and Eylea HD are ramping, at least on my TV. It’s time.
𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙐𝙋𝘿𝘼𝙏𝙀 Natan YTD: -5.6% S&P500 YTD: +12.1% TOTAL RETURNS (Jan 2022) Natan's portfolio: +110.7% *Benchmark: +42.5% S&P500: +70.4% MY POSITIONS: 30.0% | Transmedics $TMDX 15.3% | Procept BioRobotics $PRCT 12.9% | Pinduoduo $PDD 11.4% | Robinhood $HOOD 10.0% | Meta Platfor
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Regeneron is a biotech that turns lab discoveries into injectable medicines for eye disease, asthma, and cancer, selling treatments like EYLEA and Dupixent to patients worldwide.
Money comes from selling biologic drugs, mainly EYLEA and Dupixent, with gross margins around 85% and net margins near 30% on USD 14.34B annual revenue, recurring as chronic treatments.
Patents and complex manufacturing protect its biologics, but biosimilars from Amgen and Samsung Bioepis are eroding EYLEA's market share, while Dupixent faces competition from Sanofi and AbbVie.
Hold (sector percentile 65) — value B+, growth B-, profitability A-, momentum C+, revisions B. Updated daily, sector-relative, identical for every user.
